Russias VED system has always been a quiet lever in global pharmauntil now. With Russias recent VED/SSM lists updates, the market signal is clear: generic entry timing is no longer just a question of regulatory readiness. Its a question of patent intel…
Russia’s VED & SSM Lists: How to Time Generic Entry Using Patent Expiration Data Read Post »
Pharma pipelines dont fail because of science. They fail because of risk you didnt see.
Thats the uncomfortable truth behind many surprise generic entries, licensing dead-ends, and launch delays. The root cause is often the same: teams move fast on R&a…
Freedom to Operate in Pharma: The Step-by-Step FTO Analysis That Protects Your Pipeline Read Post »
Beyond the ANDA: How the 505(b)(2) Pathway Can Turn Copy Into Competitive Moat
Most pharma conversations about generics start and end with the ANDA. Its familiar, its measurable, and its often the fastest route to market. But if youre trying to build s…
Pharma IP teams are used to thinking in patent years. But in Russia, the clock can movefastand the consequences are immediate.
Russias patent-term extension landscape is changing in ways that can make or break market exclusivity, pricing strategy, and …
Russia Patent-Term Extensions: What Every Pharma IP Team Needs to Know Right Now Read Post »
Your drug patent portfolio shouldnt just sit thereit should work.
In pharma, patents are often treated like static assets: file, publish, wait. But the market doesnt reward waiting. Competitors dont pause. Regulators dont slow down. And litigationwhe…
Hospitals are sitting on a quiet competitive advantageand many are ignoring it.
In the pharmaceutical market, patent expiration isnt just a legal milestone. Its a pricing event. A supply-chain inflection point. A formulary strategy fork in the road. An…
Patent Expiration Intelligence: The GPO Contract Weapon Hospitals Are Ignoring Read Post »
Generic launches dont just happen. Theyre engineered by timelines, filings, and legal leverage.
If youre still forecasting generic drug launch dates using spreadsheets and historical averages, youre already behind. In todays market, the difference be…
The Orange Book Isnt Just a Database. Its a Talent Map.
If youre trying to find the next wave of pharma innovation, you dont start with a pitch deckyou start with the paper trail.
The FDAs Orange Book is often treated like a compliance tool: patents, e…
Biotech investors love pipeline value, but most portfolio rankings still miss the point.
A company can have a long list of programs and still be quietly destroying valuebecause the timing and probability of cash flows are treated like afterthoughts. In…
NPV and Profitability Index: How to Rank Your Biotech R&D Portfolio Read Post »
The patent cliff isnt just a pharma problemits a talent problem.
Most people talk about the patent cliff as a revenue event: when exclusivity ends, generic competition arrives, margins compress, and pipelines suddenly look urgent. But theres another cl…
Read the Patent Cliff: How Recruiters Find Biopharma Talent Before Competitors Do Read Post »
Get new actionable insights and updates from BiotechBlog
